Plasma amino acid signatures define types of pediatric diabetes.
Amino acids
Pediatric diabetes
Targeted metabolomics
Type 1 diabetes
Type 2 diabetes
Journal
Clinical nutrition ESPEN
ISSN: 2405-4577
Titre abrégé: Clin Nutr ESPEN
Pays: England
ID NLM: 101654592
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
07
03
2023
revised:
31
05
2023
accepted:
05
06
2023
pmc-release:
01
10
2024
medline:
25
9
2023
pubmed:
23
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
Metabolic biomarkers with pathophysiological relevance is lacking in pediatric diabetes. We aimed to identify novel metabolic biomarkers in pediatric type 1 (T1D) and type 2 diabetes (T2D). We hypothesized that (1) targeted plasma metabolomics, focused on plasma amino acid concentrations, could identify distinctively altered patterns in children with T1D or T2D, and (2) there are specific changes in concentrations of metabolites related to branch chain amino acids (BCAA) and arginine metabolism in children with T2D. In a pilot study, we enrolled children with T1D (n = 15) and T2D (n = 13), and healthy controls (n = 15). Fasting plasma amino acid concentrations were measured by ultra-performance liquid chromatography, and compared between the groups after adjustment for confounding factors. The mean age (SD) of participants was 16.4 (0.9) years. There were no group differences in age, gender, race/ethnicity, or 24-h protein intake. Mean BMI percentile was higher in the T2D than the T1D group or controls (p < 0.001). The T2D group had lower arginine, citrulline, glutamine, glycine, phenylalanine, methionine, threonine, asparagine and symmetric dimethylarginine (SDMA) but higher aspartate than controls, after adjusting for BMI percentiles (all p < 0.05). Children with T2D also had lower glycine but higher ornithine, proline, leucine, isoleucine, valine, total BCAA, lysine and tyrosine than those with T1D after adjusting for confounding factors (all p < 0.05). Children with T1D had lower phenylalanine, methionine, threonine, glutamine, tyrosine, asymmetric dimethylarginine (ADMA) and SDMA than controls (all p < 0.05). Children with T2D and T1D have distinct fasting plasma amino acid signatures that suggest varying pathogenic mechanisms and could serve as biomarkers for these conditions.
Sections du résumé
BACKGROUND & AIMS
Metabolic biomarkers with pathophysiological relevance is lacking in pediatric diabetes. We aimed to identify novel metabolic biomarkers in pediatric type 1 (T1D) and type 2 diabetes (T2D). We hypothesized that (1) targeted plasma metabolomics, focused on plasma amino acid concentrations, could identify distinctively altered patterns in children with T1D or T2D, and (2) there are specific changes in concentrations of metabolites related to branch chain amino acids (BCAA) and arginine metabolism in children with T2D.
METHODS
In a pilot study, we enrolled children with T1D (n = 15) and T2D (n = 13), and healthy controls (n = 15). Fasting plasma amino acid concentrations were measured by ultra-performance liquid chromatography, and compared between the groups after adjustment for confounding factors.
RESULTS
The mean age (SD) of participants was 16.4 (0.9) years. There were no group differences in age, gender, race/ethnicity, or 24-h protein intake. Mean BMI percentile was higher in the T2D than the T1D group or controls (p < 0.001). The T2D group had lower arginine, citrulline, glutamine, glycine, phenylalanine, methionine, threonine, asparagine and symmetric dimethylarginine (SDMA) but higher aspartate than controls, after adjusting for BMI percentiles (all p < 0.05). Children with T2D also had lower glycine but higher ornithine, proline, leucine, isoleucine, valine, total BCAA, lysine and tyrosine than those with T1D after adjusting for confounding factors (all p < 0.05). Children with T1D had lower phenylalanine, methionine, threonine, glutamine, tyrosine, asymmetric dimethylarginine (ADMA) and SDMA than controls (all p < 0.05).
CONCLUSIONS
Children with T2D and T1D have distinct fasting plasma amino acid signatures that suggest varying pathogenic mechanisms and could serve as biomarkers for these conditions.
Identifiants
pubmed: 37739658
pii: S2405-4577(23)00149-3
doi: 10.1016/j.clnesp.2023.06.005
pmc: PMC10518839
mid: NIHMS1909178
pii:
doi:
Substances chimiques
Glutamine
0RH81L854J
Methionine
AE28F7PNPL
Racemethionine
73JWT2K6T3
Arginine
94ZLA3W45F
Citrulline
29VT07BGDA
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21-28Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK129821
Pays : United States
Informations de copyright
Copyright © 2023 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors have no conflict of interest to disclose.
Références
Diabetes Res Clin Pract. 2023 Mar;197:110559
pubmed: 36758641
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1755-e1762
pubmed: 33410917
Science. 1992 Feb 7;255(5045):721-3
pubmed: 1371193
Front Endocrinol (Lausanne). 2022 Jan 04;12:795044
pubmed: 35058883
Curr Med Chem. 2022;29(1):99-113
pubmed: 34269660
J Endocrinol. 2011 Oct;211(1):87-97
pubmed: 21784771
Curr Opin Clin Nutr Metab Care. 2019 Jan;22(1):91-95
pubmed: 30461450
Biochim Biophys Acta. 1989 Sep 19;1013(2):133-43
pubmed: 2669974
Eur J Nutr. 2018 Dec;57(8):2805-2817
pubmed: 29052766
Clin Nutr. 2021 Jun;40(6):4209-4215
pubmed: 33583659
Nat Rev Endocrinol. 2014 Dec;10(12):723-36
pubmed: 25287287
Amino Acids. 2013 Sep;45(3):463-77
pubmed: 23615880
Diabetes. 2020 Oct;69(10):2086-2093
pubmed: 32843567
Annu Rev Med. 1975;26:245-58
pubmed: 1096762
Diabetes Metab Res Rev. 2017 Feb;33(2):
pubmed: 27393712
MMWR Morb Mortal Wkly Rep. 2020 Feb 14;69(6):161-165
pubmed: 32053581
Am J Clin Nutr. 2002 Dec;76(6):1302-7
pubmed: 12450897
Diabetes Care. 2001 May;24(5):875-80
pubmed: 11347747
Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38
pubmed: 34964875
Annu Rev Nutr. 1984;4:409-54
pubmed: 6380539
Diabetes Obes Metab. 2019 Feb;21(2):397-401
pubmed: 30146690
Curr Diabetes Rev. 2020;16(6):532-537
pubmed: 31057117
J Clin Endocrinol Metab. 2020 Apr 1;105(4):
pubmed: 31782507
J Physiol. 1997 Mar 15;499 ( Pt 3):625-35
pubmed: 9130159
Pediatr Diabetes. 2020 Nov;21(7):1064-1073
pubmed: 32562358
JAMA. 2014 May 7;311(17):1778-86
pubmed: 24794371
J Diabetes Res. 2016;2016:2108909
pubmed: 26881241
J Nutr. 2007 Jun;137(6 Suppl 1):1549S-1555S; discussion 1573S-1575S
pubmed: 17513423
Cell Metab. 2017 Jan 10;25(1):43-56
pubmed: 28094011
J Nutr. 2018 Feb 1;148(2):185-193
pubmed: 29490093
Nutrients. 2015 Mar 24;7(4):2101-8
pubmed: 25811109
Diabetes Care. 2020 Jan;43(1):5-12
pubmed: 31753960
Pediatr Obes. 2013 Feb;8(1):52-61
pubmed: 22961720
Diabetes Care. 2016 May;39(5):833-46
pubmed: 27208380
Mol Metab. 2021 Oct;52:101261
pubmed: 34044180
Diabetes. 2021 Aug;70(8):1898-1909
pubmed: 34021044
Baillieres Clin Endocrinol Metab. 1996 Oct;10(4):589-601
pubmed: 9022953
Comp Biochem Physiol C Toxicol Pharmacol. 2003 Apr;134(4):521-7
pubmed: 12727302
Curr Opin Clin Nutr Metab Care. 2016 Jan;19(1):62-6
pubmed: 26560519
Sci Rep. 2019 May 7;9(1):7010
pubmed: 31065046
Front Endocrinol (Lausanne). 2022 Mar 09;13:856958
pubmed: 35355556
Nutr Metab (Lond). 2020 Sep 25;17:80
pubmed: 32983244
J Clin Endocrinol Metab. 2015 Mar;100(3):E463-8
pubmed: 25423564
N Engl J Med. 1969 Oct 9;281(15):811-6
pubmed: 5809519
Diabetes Care. 2018 May;41(5):917-928
pubmed: 29567642
Endocrinology. 2006 Sep;147(9):4160-8
pubmed: 16777975
Diabetologia. 2020 Oct;63(10):2040-2048
pubmed: 32894314
Science. 2019 Feb 8;363(6427):582-583
pubmed: 30733403
Diabetes. 2013 Mar;62(3):912-22
pubmed: 23160531